<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02273817</url>
  </required_header>
  <id_info>
    <org_study_id>CICE-NASU-05SB03-CE</org_study_id>
    <nct_id>NCT02273817</nct_id>
  </id_info>
  <brief_title>A Study Comparing The Bioequivalence Of Ciclesonide Nasal Spray (Apotex, Inc.) To That Of Omnaris™ Nasal Spray (Sepracor, Inc.) In The Treatment Of Seasonal Allergic Rhinitis</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Parallel-group Study Comparing the Bioquivalence of Ciclesonide Nasal Spray(Apotex Inc.) to That of Omnaris ™Nasal Spray (Sepracor, Inc.) in the Treatment of Seasonal Allergic Rhinitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Apotex Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Apotex Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to evaluate the equivalence of generic ciclesonide nasal spray with that of the&#xD;
      marketed drug, Omnaris™ nasal spray, in the treatment of seasonal allergic rhinitis, and to&#xD;
      evaluate the safety and tolerability of generic ciclesonide nasal spray compared with&#xD;
      Omnaris™ nasal spray.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment Of Seasonal Allergic Rhinitis</measure>
    <time_frame>5 months</time_frame>
    <description>Change from baseline in the combined reflective Total nasal symptom score (TNSS) (combined AM and PM reflective scores of runny nose, nasal congestion, nasal itchiness, and sneezing).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment Of Seasonal Allergic Rhinitis</measure>
    <time_frame>5 months</time_frame>
    <description>Change from baseline in the combined AM and PM instantaneous scores of runny nose, nasal congestion, nasal itchiness, and sneezing.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">580</enrollment>
  <condition>Seasonal Allergic Rhinitis</condition>
  <arm_group>
    <arm_group_label>Ciclesonide Nasal Spray (Apotex, Inc.)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ciclesonide nasal spray&#xD;
Dosage form: contain the aqueous medium of each metered-dose pump spray formulation unit plus the active ingredient, ciclesonide.&#xD;
Strength: 50 μg per actuation.&#xD;
Batch/Lot number (Expiry date): JM6697 (May 2012)&#xD;
Manufacturer: Apotex, Inc.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Omnaris™ nasal spray</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Omnaris™ Nasal Spray,&#xD;
Dosage form: contain the aqueous medium of each metered-dose pump spray formulation unit plus the active ingredient, ciclesonide&#xD;
Strength: 50 μg per actuation&#xD;
Batch/Lot number (Expiry date): 131657 (03/2012)&#xD;
Manufacturer: Sepracor, Inc.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo&#xD;
Dosage form: Contain the aqueous medium of each metered-dose pump spray formulation unit minus the active ingredient, ciclesonide.&#xD;
Batch/Lot number (Expiry date): JR3808 (Nov 2012)&#xD;
Manufacturer: Apotex, Inc.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ciclesonide nasal spray, 50 μg per actuation.</intervention_name>
    <description>During placebo lead-in period: patients received placebo nasal spray, two actuations in each nostril once daily for 7 days.&#xD;
During treatment period: subjects were then assigned to one of the following three treatments according to the randomization scheme:&#xD;
Ciclesonide nasal spray: 50 μg per actuation, two actuations in each nostril once daily (200 μg per day) for 14 days.&#xD;
Omnaris™ nasal spray: 50 μg per actuation, two actuations in each nostril once daily (200 μg per day) for 14 days.&#xD;
Placebo nasal spray: 0 μg per actuation, two actuations in each nostril once daily for 14 days.</description>
    <arm_group_label>Ciclesonide Nasal Spray (Apotex, Inc.)</arm_group_label>
    <arm_group_label>Omnaris™ nasal spray</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  If female of childbearing potential, is not pregnant (confirmed by negative urine&#xD;
             pregnancy test) or lactating and must have used reliable birth control measures&#xD;
             throughout the study.&#xD;
&#xD;
          -  At least a 2-year reliable medical history consistent with SAR&#xD;
&#xD;
          -  Positive skin test within 12 months of screening to at least one seasonal allergen&#xD;
             present in the geographical area&#xD;
&#xD;
          -  Capable of tolerating intranasal application of the IMP, willing and able to comply&#xD;
             with the requirements of the protocol&#xD;
&#xD;
          -  No clinically significant findings in physical and nasal examinations, and medical&#xD;
             history.&#xD;
&#xD;
          -  A reflective TNSS of at least 6 (out of 12) in the 24 hours prior to placebo lead-in&#xD;
             visit.&#xD;
&#xD;
          -  Successfully complete the placebo lead-in period.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  - Signs or symptoms of nasal polyps, deviated septum, or any other condition which, in&#xD;
             the opinion of the Investigator, could resulted in erroneous study data.&#xD;
&#xD;
          -  Undergo nasal surgery or had nasal trauma within 3 months of screening.&#xD;
&#xD;
          -  Active respiratory conditions or respiratory tract infection that require antibiotic&#xD;
             treatment within 2 weeks of screening&#xD;
&#xD;
          -  Persistent allergic rhinitis (PAR) that does not require or not expected to require&#xD;
             active PAR treatment during the study period.&#xD;
&#xD;
          -  Evidence of any unstable or clinically significant conditions that would place the&#xD;
             subject at increased risk of complications, interfere with study participation, or&#xD;
             confound any of the study objectives.&#xD;
&#xD;
          -  Presence or history of clinically significant conditions which in the opinion of the&#xD;
             Investigator would have compromised the safety of the subject or the conduct of the&#xD;
             study.&#xD;
&#xD;
          -  Use of corticosteroids, intranasal cromolyn, Leukotriene inhibitors, long or short&#xD;
             acting antihistamines, intranasal or systemic decongestants prior to the start of the&#xD;
             single-blind, placebo lead-in visit within the time periods specified in the protocol&#xD;
             or receiving immunotherapy.&#xD;
&#xD;
          -  Use of an investigational drug within 30 days before screening or during the study.&#xD;
&#xD;
          -  Known or suspected hypersensitivity to corticosteroids.&#xD;
&#xD;
          -  Inability to avoid exposure to chicken pox or measles.&#xD;
&#xD;
          -  Infection requiring oral antibiotic treatment 2 weeks prior to screening.&#xD;
&#xD;
          -  Previously identified as a placebo responder or known as a non responder to&#xD;
             corticosteroids.&#xD;
&#xD;
          -  History of alcohol, drug, or substance abuse in the 12 months prior to Visit 1&#xD;
             (screening).&#xD;
&#xD;
          -  Positive for hepatitis B or C, or human immunodeficiency virus (HIV).&#xD;
&#xD;
          -  Uncooperative or non compliant.&#xD;
&#xD;
          -  Female subjects who planned to become pregnant during the conduct of the study.&#xD;
&#xD;
          -  Current smoker (former smokers had to be 6 months smoke free).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>February 2012</verification_date>
  <study_first_submitted>October 14, 2014</study_first_submitted>
  <study_first_submitted_qc>October 23, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 24, 2014</study_first_posted>
  <last_update_submitted>October 23, 2014</last_update_submitted>
  <last_update_submitted_qc>October 23, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 24, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
    <mesh_term>Rhinitis, Allergic, Seasonal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ciclesonide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

